Loading…
Aptevo Therapeutics Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in APVO.
▼ -100.0% over 5Y.
today you would have $0.00▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $9.43 | $1,551.60 | $106,080.48 | $1,359,705.63 | |
| P/E | — | — | — | — | 1.9x |
| P/S | — | — | — | — | 4.8x |
| P/B | 0.7x | 0.5x | 1.3x | 0.3x | 0.8x |
| EPS | -$87.27 | -$31,460.23 |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| XRTXXORTX Therapeutics Inc. | $2.34 | — | 1.6x | — | -99.24% | $4.25M |
| ELABPMGC Holdings Inc. | $5.31 | — | 0.2x | — | -105.22% | $4.3M |
| GRIGRI Bio, Inc. | $1.92 | — | 0.4x | — | -142.02% | $4.2M |
| JAGXJaguar Health, Inc. | $0.81 |
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Company description provided by Yahoo Finance.
| -$527,606.06 |
| $729,727.27 |
| Profit margin | — | — | — | — | 257.77% |
| ROE | -145.93% | -149.40% | -507.47% | -142.47% | 44.66% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| 0.0x |
| — |
| — |
| -548.83% |
| $4.19M |
| REVBRevelation Biosciences Inc | $1.05 | 0.0x | 0.4x | — | -154.77% | $4.18M |
| XAIRBeyond Air, Inc. | $4.48 | 0.0x | 0.4x | — | -519.51% | $4.41M |